100
Participants
Start Date
November 14, 2016
Primary Completion Date
February 3, 2020
Study Completion Date
December 31, 2025
Abemaciclib
Administered orally
Pembrolizumab
Administered IV
Anastrozole
Administered orally
Tri-Service General Hospital, Neihu Taipei
Taipei Medical University- Shuang Ho Hospital, New Taipei City
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven
Centre Hospitalier Universitaire Sart Tilman, Liège
Hospital San Pedro de Alcantara, Cáceres
National Taiwan University Hospital, Taipei
Memorial Sloan Kettering Cancer Center, New York
IRCCS Ospedale San Raffaele, Milan
Hospital Universitario 12 de Octubre, Madrid
Hospital Madrid Norte Sanchinarro, Madrid
Hopital Larrey, Toulouse
Hôpital Arnaud de Villeneuve - CHU Montpellier, Montpellier
Istanbul Universitesi-Cerrahpasa Cerrahpasa Tip Fakultesi Yerleskesi, Istanbul
Ege Universitesi Hastanesi, Izmir
Istituto Scientifico Romagnolo - Studio e la Cura dei Tumori, Meldola
Karmanos Cancer Institute, Detroit
Karmanos Cancer Institute, Farmington Hills
Centre Oscar Lambret, Lille
Highlands Oncology Group - Duplicate 2, Springdale
Chi Mei Hospital - Liouying Branch, Tainan City
University of Colorado School of Medicine, Aurora
Univ of California San Francisco, San Francisco
Dana Farber Cancer Institute, Boston
Hospital Nuestra Senora de Sonsoles, Ávila
Merck Sharp & Dohme LLC
INDUSTRY
Eli Lilly and Company
INDUSTRY